Trial Profile
A Phase II Study of OXALIPLATIN and GEMCITABINE in Combination with IFOSFAMIDE plus RITUXIMAB (R-GIFOX) as 2nd-line Chemotherapy in Relapsed and Primary Refractory Lymphoma.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2011
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Rituximab (Primary) ; Ifosfamide
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms R-GIFOX
- 27 Jul 2011 New trial record